A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004)

被引：0
|
作者：
Coombes, RC
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2461 / 2461
页数：1
相关论文
共 50 条
  • [1] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004)
    Coombes, R. C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16) : 1746 - 1746
  • [2] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092
  • [3] Exemestane after two to three years of tamoxifen in postmenopausal women with curable breast cancer
    Delozier, T
    BULLETIN DU CANCER, 2004, 91 (7-8) : 581 - 581
  • [4] Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    Fallowfield, LJ
    Bliss, JM
    Porter, LS
    Price, MH
    Snowdon, CF
    Jones, SE
    Coombes, RC
    Hall, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 910 - 917
  • [5] Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer.
    Thompson, D
    Taylor, DCA
    Montoya, EL
    Winer, E
    Weinstein, MC
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S218 - S218
  • [6] Exemestane following tamoxifen in postmenopausal women with primary breast cancer
    Mouridsen, HT
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3833 - 3834
  • [7] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Goss, PE
    Ingle, JN
    Martino, S
    Robert, NJ
    Muss, HB
    Piccart, MJ
    Castiglione, M
    Tu, D
    Shepherd, LE
    Pritchard, KI
    Livingston, RB
    Davidson, NE
    Norton, L
    Perez, EA
    Abrams, JS
    Therasse, P
    Palmer, MJ
    Pater, JL
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1793 - 1802
  • [8] Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
    Rea, D.
    Hasenburg, A.
    Seynaeve, C.
    Jones, S. E.
    Vannetzel, J-M
    Paridaens, R.
    Markopoulos, C.
    Hozumi, Y.
    Putter, H.
    Hille, E.
    Asnar, L.
    Urbanski, R.
    van de Velde, C. H.
    Bartlett, J. M. S.
    Smeets, J.
    Kieback, D. G.
    CANCER RESEARCH, 2009, 69 (24) : 487S - 487S
  • [9] Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer
    Gallen, M
    Alonso, C
    Ojeda, B
    Viladiu, P
    Beltran, M
    Borras, J
    Pelegri, A
    Tusquets, I
    Barnadas, A
    Arcusa, A
    Bastus, R
    Balil, A
    Batiste-Alentorn, E
    Boleda, M
    Badia, MA
    Garau, I
    Guash, I
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S40 - S40
  • [10] The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen updated survival analysis
    Coombes, RC
    Hall, E
    Snowdon, CF
    Bliss, JM
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S7 - S7
12345